Truist Financial Initiates Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $172
Barclays Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $200
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Positive Phase 3 Results and Market Expansion Drive Buy Rating for Jazz Pharmaceuticals
Morgan Stanley Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Maintains Target Price $140
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
Jazz Pharmaceuticals Analyst Ratings
RBC Lifts Price Target on Jazz Pharmaceuticals to $175 From $174, Keeps Outperform Rating
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Stifel Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $230
Jefferies Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $154
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $205
Needham Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Maintains Target Price $120
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $200
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $200
Stifel Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $230